Figure 3.

CDC25 inhibitors affect cell viability and the cell cycle. (A) HeLa cells were treated with increasing amounts of compounds and cell viability was determined. (B) Cells were treated in the presence or the absence of NAC before administration of compounds at doses ~3x IC₅₀ (5 μM) and cell viability was determined. (C) Cells were treated with the indicated compounds (10 μM, 15 h). NSC663284 was used as comparison (5 µM, 15 h). DNA was stained with DAPI. (D) HeLa cells were synchronized at G2/M by treatment with Thymidine (1 mM, 15 h), release in full medium followed by addition of the CDK1 inhibitor Ro-3306 (9 μM, 15 h). Five hours upon release from Ro-3306, the indicated compounds were added (10 μM) and cells were harvested and analyzed 12 h upon release from Ro-3306. (E) HeLa cells were synchronized at G1/S by 2x thymidine block-release, compounds (10 μM) were added at 5 h and cells were analyzed at 12 h from release.